BIOC:NSD-Biocept, Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 4.36

Change

+0.16 (+3.81)%

Market Cap

USD 0.06B

Volume

0.52M

Average Target Price

USD 2.00 (-54.13%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company's Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA. In addition, it offers laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians to determine the treatment plan for their patients, as well as to pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California. Address: 5810 Nancy Ridge Drive, San Diego, CA, United States, 92121

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

+5.57 (+1.86%)

USD43.89B 61.31 36.64
DXCM DexCom, Inc

-2.17 (-0.54%)

USD38.52B 173.65 108.43
IDXX IDEXX Laboratories, Inc

+8.54 (+2.26%)

USD32.14B 69.09 46.81
EXAS Exact Sciences Corporation

+2.00 (+2.05%)

USD14.67B N/A N/A
GH Guardant Health, Inc

-2.81 (-2.51%)

USD11.12B N/A N/A
ICLR ICON Public Limited Company

+2.90 (+1.58%)

USD9.64B 29.89 20.21
QDEL Quidel Corporation

+1.87 (+0.95%)

USD8.25B 53.92 33.44
PRAH PRA Health Sciences, Inc

+1.86 (+1.91%)

USD6.22B 29.56 17.69
NTRA Natera, Inc

+1.43 (+2.08%)

USD5.77B N/A N/A
SYNH Syneos Health, Inc

+1.81 (+3.51%)

USD5.36B 28.65 16.75

ETFs Containing BIOC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 50.34% 69% D+ 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.34% 69% D+ 85% B
Trailing 12 Months  
Capital Gain -46.17% 17% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.17% 17% F 12% F
Trailing 5 Years  
Capital Gain -99.79% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.79% 3% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -63.95% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.95% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.56% N/A N/A 53% F
Risk Adjusted Return -232.06% N/A N/A N/A N/A
Market Capitalization 0.06B 22% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.21 79% C+ 48% F
Price / Cash Flow Ratio -2.44 49% F 67% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -133.91% 17% F 9% F
Return on Invested Capital -323.76% 5% F 2% F
Return on Assets -56.44% 12% F 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.13 97% A+ 93% A
Short Percent 2.37% 79% C+ 58% F
Beta 0.64 85% B 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector